

NYRx Education & Outreach Pharmacy Newsletter

July 2026



[Welcome](#) | [Highlights](#) | [About](#) | [Quicklinks](#) | [Calendar](#) | [Resources](#) | [Contact](#)

Welcome!

In this issue, you'll find trending topics, information about the NYRx Education & Outreach team, helpful links, calendar events, links to resources, and how to contact us.

Highlights

NYRx Formulary Update: Prenatal Vitamins

On **June 4, 2026**, NYRx, the Medicaid Pharmacy Program, updated prenatal vitamin coverage. Prenatal vitamins covered by NYRx meet or exceed the recommended daily intake values for Folic Acid and Iron per the United State Preventative Services Task Force (USPSTF) and the American College of Obstetrics and Gynecology (ACOG). The following options, which allow for up to a 90-day supply and do not require a prior authorization (PA), are available for New York Medicaid members:

- CompleteNate Chewable Tablet
- Elite OB Caplet
- M-Natal Plus Tablet
- PNV DHA Softgel
- Prenatal Vitamin Tablet
- Prenatal Vitamins Plus Low Iron Tablet
- Select-OB Chewable Caplet
- Se-Natal 19 Chewable
- Se-Natal 19 Tablet
- Thrivite RX Tablet
- Trinatal RX 1 Tablet
- Westab Plus Tablet

For more information, click [here](#).

Cost Optimization Program Update

Starting on **July 16, 2026**, the following drugs will require a Manual Review by NYRx for coverage approval:

- cephalexin 750 mg capsule, 250 mg, 500 mg tablet
- clindamycin phosphate 1% foam (Evoclin)
- clindamycin/benzoyl peroxide 1.2%-3.75% gel
- clindamycin/tretinoin 1.2% 0.025% gel
- clonidine hcl 0.05 mg tablet
- dexamethasone (dexylt) 0.25 mg tablet
- doxycycline monohydrate 75 mg, 150 mg capsule
- Fenofibrate 50 mg, 150 mg capsule (Lipofen)
- fenoprofen 400 mg capsule (Nalfon)
- Fenoprofen 600 mg tablet (Nalfon)
- folic acid (Quiofic) 0.2 mg/mL solution
- glipizide 15 mg tablet
- granisol 2 mg/10 mL solution

- halobetasol 0.05% foam
- indomethacin 25 mg/5 mL suspension
- ketoprofen 200 mg ER capsule
- Neo-Synalar 0.5%-0.025% cream
- tazarotene foam (Fabior)
- tolmetin sodium 200 mg tablet

These drugs will be rejected with the National Council for Prescription Drug Programs (NCPDP) Reject Code "75-MR, Manual Review Required." Claims with existing Prior Authorizations will also be rejected for edit 00254 "Service Code not equal to PA." For more information and the most up-to-date list, please click [here](#).

NYRx Brand Less Than Generic Program Update

Effective **July 16, 2026**, the following changes will be made to the Dispense Brand Name Drug When Less Expensive Than the Generic Program:

- Bosulif® tablet, Janumet®, Januvia®, and Xyrem® will be ADDED to the program.
- Farxiga® and Ravicti® will be REMOVED from the program.

For more information and the most up-to-date list, please click [here](#).

Discontinued Drug Coverage for Terminated Labelers

Effective **July 1, 2026**, the following drug manufacturers voluntarily withdrew from participation in the Medicaid Drug Rebate Program. As a result, the NYRx, Medicaid Pharmacy Program, will no longer provide coverage for drugs manufactured by the manufacturers listed below:

- Alexion Pharmaceuticals, Inc
- Clovis Oncology, Inc
- Eiger Biopharmaceuticals
- Estiva Generics
- Innovida Pharmaceutique Corporation
- Pharmaceutica North America, Inc
- Q Biomed, Inc
- Seton Pharmaceuticals, Inc
- Sti Pharma, LLC
- Vantive US Healthcare, LLC
- Wyeth Pharmaceuticals, LLC
- Xspire Pharma, LLC
- Yiling Pharmaceutical, Inc
- Zambon USA, LTD

For more information, click [here](#).

About Us

The NYRx Education & Outreach team serves as a liaison between all stakeholders and NYRx to support care coordination. Clinical liaisons are trained to support and help solve complex pharmacy cases for:

- Managed Care Plans
- Case workers and New York State agencies
- Prescribers and pharmacies with questions regarding NYRx drug coverage, prior approval requirements, and NYRx enrolled pharmacies
- Complex care coordination for populations such as HIV/AIDS, Hemophilia, Foster Care Children, Serious Mental Illness, Substance Use Disorder, and Hepatitis C

Quicklinks

- [NYRx Brand Less Than Generic Program Updates](#)
- [NYRx eMedNY Formulary File](#)
- [NYRx Preferred Diabetic Supply Program](#)
- [NYRx Preferred Drug List](#)
- [NYRx Preferred Drug Quick List](#)

Calendar

Office Hour Q&A Pop-In

[Tuesday & Thursday 12:00 PM – 1:00 PM ET](#)

Weekly Webinar

To register for a webinar, please visit the [NYRx E&O website](#):

- Pharmacy Webinar Wednesday 12:00 PM – 1:00 PM ET
- NYRx, the Medicaid Pharmacy Program Friday 12:00 PM – 1:00 PM ET

Resources

- [NYRx E&O Website](#)
- [NYRx E&O YouTube Channel](#)
- [New York Public Health Now Podcast](#)

Contact Us

- [NYRx E&O Mailbox](#)
- NYRx E&O Call Center at 1-833-967-7310, M – F, 8:00 AM – 5:00 PM ET, Excludes Holidays
- The NYRx E&O team is available to meet with you. To request a meeting, click [here](#).